EBIT at other companies
Other financials
Where this comes from
Calculated from BioCryst Pharmaceuticals’s reported figures.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's EBIT?
- BioCryst Pharmaceuticals (BCRX) reported EBIT of -$701.6M in Q1 2026.
- How has BioCryst Pharmaceuticals's EBIT changed year-over-year?
- BioCryst Pharmaceuticals's EBIT decreased by 3405.2% year-over-year, from $21.23M to -$701.6M.
- What is the long-term trend for BioCryst Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's EBIT has grown at a 17.7% compound annual growth rate (CAGR), from -$177.72M to $340.99M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.